INTERVIEW: Deltex Medical Group Positioned Well and Increased Interest

Deltex Medical Group (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about its 2017 year end results. Ewan talks us through the highlights, explains whats been happening operationally this year, the strategy for the next 12 months and what investors can look forward to in the near future.

Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s proprietary ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhancedhaemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.

Deltex Medical’s CardioQ-ODM+ platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamicallystable patients.

 

Company goal

Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Company’s focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Company aims to provide clinicians with a single platform, a ‘haemodynamicworkstation’, which offers them a range of technologies from simple to sophisticated to be deployed according to the patient’s condition and skill and expertise of the user. Doing this will enable the Company to partner healthcare providers to support modern haemodynamic management across the whole hospital.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Deltex Medical Group Plc

    More articles like this

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    Tirupati Graphite plc

    Tirupati Graphite: Business Development Update

    Tirupati Graphite PLC (LON:TGR) is a fully integrated specialist graphite and graphene producer, with operations in Madagascar and India. The Company is delivering on this strategy by being fully integrated from mine to graphene. Its global

    Fidelity Special Values

    FTSE 100 on track for positive March quarter end

    UK’s FTSE 100 was set for a positive end to the March quarter and touched fresh highs on Thursday after a rally last week, bolstered broadly by miner and bank stocks on the last trading day

    Silver futures rise on spot demand

    Silver prices on Wednesday marginally rose Rs 18 to Rs 74,536 per kilogram in futures trade as participants widened their bets on a firm spot demand. On the Multi Commodity Exchange, silver contracts for May delivery